Atlas Trials

Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN

Clinical trial NCT03726775 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03726775
Sponsor
Groupe Oncologie Radiotherapie Tete et Cou
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HNSCC
Start date
2019-07-17
Primary completion
2026-07-01
Enrollment
61

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.